schliessen

Filtern

 

Bibliotheken

Republished: The clinical spectrum of pulmonary aspergillosis

The clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients... Full description

Journal Title: Postgraduate Medical Journal Vol.91(1077), p.403
Main Author: Kosmidis, Chris
Other Authors: Denning, David W
Format: Electronic Article Electronic Article
Language: English
Subjects:
Publisher: BMJ Publishing Group LTD
Created: Jul 2015
ID: ISSN: 00325473 ; DOI: 10.1136/postgradmedj-2014-206291rep
Link: http://search.proquest.com/docview/1847948151/?pq-origsite=primo
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: proquest1847948151
title: Republished: The clinical spectrum of pulmonary aspergillosis
format: Article
creator:
  • Kosmidis, Chris
  • Denning, David W
subjects:
  • Health Risk Assessment
  • Surveillance
  • Cystic Fibrosis
  • Lung Diseases
  • Asthma
  • Transplants & Implants
  • Steroids
  • Pathogenesis
  • Infections
  • Risk Factors
  • Pathogens
  • Bronchitis
  • Chemotherapy
  • Medical Prognosis
  • Mortality
  • Neutropenia
  • Aspergillus Lung Disease
ispartof: Postgraduate Medical Journal, Vol.91(1077), p.403
description: The clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids. A high index of suspicion is required in patients without the classical risk factors as early presentation is usually silent and non-specific, pyrexia uncommon and timely treatment is crucial for survival. Invasive aspergillosis has also been diagnosed in normal hosts after massive exposure to fungal spores. Chronic pulmonary aspergillosis affects patients without obvious immune compromise, but with an underlying lung condition such as COPD or sarcoidosis, prior or concurrent TB or non-tuberculous mycobacterial disease. Aspergillus bronchitis may be responsible for persistent respiratory symptoms in patients with Aspergillus detected repeatedly in sputum without evidence of parenchymal Aspergillus disease, especially in patients with bronchiectasis and cystic fibrosis. Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated. Changes in the classification of Aspergillus allergic lung disease have been proposed recently. Cases of extrinsic allergic alveolitis and chronic pulmonary aspergillosis have been observed after Aspergillus exposure. Asymptomatic colonisation of the respiratory tract needs close monitoring as it can lead to clinical disease especially with ongoing immunosuppression. The various syndromes should be viewed as a semicontinuous spectrum of disease and one form may evolve into another depending on the degree of ongoing immunosuppression.
language: eng
source:
identifier: ISSN: 00325473 ; DOI: 10.1136/postgradmedj-2014-206291rep
fulltext: no_fulltext
issn:
  • 00325473
  • 0032-5473
url: Link


@attributes
ID274219983
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid1847948151
sourceidproquest
recordidTN_proquest1847948151
sourcesystemOther
pqid1847948151
galeid430456023
display
typearticle
titleRepublished: The clinical spectrum of pulmonary aspergillosis
creatorKosmidis, Chris ; Denning, David W
publisherBMJ Publishing Group LTD
creationdateJul 2015
ispartofPostgraduate Medical Journal, Vol.91(1077), p.403
identifierISSN: 00325473 ; DOI: 10.1136/postgradmedj-2014-206291rep
subjectHealth Risk Assessment ; Surveillance ; Cystic Fibrosis ; Lung Diseases ; Asthma ; Transplants & Implants ; Steroids ; Pathogenesis ; Infections ; Risk Factors ; Pathogens ; Bronchitis ; Chemotherapy ; Medical Prognosis ; Mortality ; Neutropenia ; Aspergillus Lung Disease
descriptionThe clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids. A high index of suspicion is required in patients without the classical risk factors as early presentation is usually silent and non-specific, pyrexia uncommon and timely treatment is crucial for survival. Invasive aspergillosis has also been diagnosed in normal hosts after massive exposure to fungal spores. Chronic pulmonary aspergillosis affects patients without obvious immune compromise, but with an underlying lung condition such as COPD or sarcoidosis, prior or concurrent TB or non-tuberculous mycobacterial disease. Aspergillus bronchitis may be responsible for persistent respiratory symptoms in patients with Aspergillus detected repeatedly in sputum without evidence of parenchymal Aspergillus disease, especially in patients with bronchiectasis and cystic fibrosis. Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated. Changes in the classification of Aspergillus allergic lung disease have been proposed recently. Cases of extrinsic allergic alveolitis and chronic pulmonary aspergillosis have been observed after Aspergillus exposure. Asymptomatic colonisation of the respiratory tract needs close monitoring as it can lead to clinical disease especially with ongoing immunosuppression. The various syndromes should be viewed as a semicontinuous spectrum of disease and one form may evolve into another depending on the degree of ongoing immunosuppression.
languageeng
source
version8
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
backlink$$Uhttp://search.proquest.com/docview/1847948151/?pq-origsite=primo$$EView_record_in_ProQuest_(subscribers_only)
search
creatorcontrib
0Kosmidis, Chris
1Denning, David W
titleRepublished: The clinical spectrum of pulmonary aspergillosis
descriptionThe clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids. A high index of suspicion is required in patients without the classical risk factors as early presentation is usually silent and non-specific, pyrexia uncommon and timely treatment is crucial for survival. Invasive aspergillosis has also been diagnosed in normal hosts after massive exposure to fungal spores. Chronic pulmonary aspergillosis affects patients without obvious immune compromise, but with an underlying lung condition such as COPD or sarcoidosis, prior or concurrent TB or non-tuberculous mycobacterial disease. Aspergillus bronchitis may be responsible for persistent respiratory symptoms in patients with Aspergillus detected repeatedly in sputum without evidence of parenchymal Aspergillus disease, especially in patients with bronchiectasis and cystic fibrosis. Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated. Changes in the classification of Aspergillus allergic lung disease have been proposed recently. Cases of extrinsic allergic alveolitis and chronic pulmonary aspergillosis have been observed after Aspergillus exposure. Asymptomatic colonisation of the respiratory tract needs close monitoring as it can lead to clinical disease especially with ongoing immunosuppression. The various syndromes should be viewed as a semicontinuous spectrum of disease and one form may evolve into another depending on the degree of ongoing immunosuppression.
subject
0Health Risk Assessment
1Surveillance
2Cystic Fibrosis
3Lung Diseases
4Asthma
5Transplants & Implants
6Steroids
7Pathogenesis
8Infections
9Risk Factors
10Pathogens
11Bronchitis
12Chemotherapy
13Medical Prognosis
14Mortality
15Neutropenia
16Aspergillus Lung Disease
general
0English
1BMJ Publishing Group LTD
210.1136/postgradmedj-2014-206291rep
3Medical Database
4ProQuest Science Journals
5STEM Database (ProQuest)
6Health & Medical Collection (Alumni edition)
7Medical Database (Alumni edition)
8Science Database (Alumni edition)
9Health & Medical Collection
10ProQuest Central
11ProQuest Hospital Collection
12Hospital Premium Collection (Alumni edition)
13ProQuest Health & Medical Complete
14ProQuest Medical Library
15ProQuest Central (new)
16ProQuest Central K-12
17ProQuest Central Korea
18Health Research Premium Collection
19Health Research Premium Collection (Alumni edition)
20ProQuest Central Essentials
21ProQuest Central China
sourceidproquest
recordidproquest1847948151
issn
000325473
10032-5473
rsrctypereview
creationdate2015
searchscope
01000273
11000283
21006385
31006761
41006762
51006765
61007067
71007945
81008886
91009127
101009156
111009386
1210000039
1310000047
1410000118
1510000119
1610000155
1710000156
1810000157
1910000158
2010000164
2110000255
2210000256
2310000257
2410000258
2510000270
2610000271
2710000281
2810000300
29proquest
scope
01000273
11000283
21006385
31006761
41006762
51006765
61007067
71007945
81008886
91009127
101009156
111009386
1210000039
1310000047
1410000118
1510000119
1610000155
1710000156
1810000157
1910000158
2010000164
2110000255
2210000256
2310000257
2410000258
2510000270
2610000271
2710000281
2810000300
29proquest
alttitlePostgraduate Medical Journal
lsr43
01000273true
11000283true
21006385true
31006761true
41006762true
51006765true
61007067true
71007945true
81008886true
91009127true
101009156true
111009386true
1210000039true
1310000047true
1410000118true
1510000119true
1610000155true
1710000156true
1810000157true
1910000158true
2010000164true
2110000255true
2210000256true
2310000257true
2410000258true
2510000270true
2610000271true
2710000281true
2810000300true
startdate20150701
enddate20150701
citationpf 403 vol 91 issue 1077
lsr30VSR-Enriched:[pages, eissn, pqid, galeid]
sort
titleRepublished: The clinical spectrum of pulmonary aspergillosis
authorKosmidis, Chris ; Denning, David W
creationdate20150701
lso0120150701
facets
frbrgroupid7548867395938884925
frbrtype5
newrecords20170306
languageeng
creationdate2015
topic
0Health Risk Assessment
1Surveillance
2Cystic Fibrosis
3Lung Diseases
4Asthma
5Transplants & Implants
6Steroids
7Pathogenesis
8Infections
9Risk Factors
10Pathogens
11Bronchitis
12Chemotherapy
13Medical Prognosis
14Mortality
15Neutropenia
16Aspergillus Lung Disease
collection
0Medical Database
1ProQuest Science Journals
2STEM Database (ProQuest)
3Health & Medical Collection (Alumni edition)
4Medical Database (Alumni edition)
5Science Database (Alumni edition)
6Health & Medical Collection
7ProQuest Central
8ProQuest Hospital Collection
9Hospital Premium Collection (Alumni edition)
10ProQuest Health & Medical Complete
11ProQuest Medical Library
12ProQuest Central (new)
13ProQuest Central K-12
14ProQuest Central Korea
15Health Research Premium Collection
16Health Research Premium Collection (Alumni edition)
17ProQuest Central Essentials
18ProQuest Central China
prefilterreviews
rsrctypereviews
creatorcontrib
0Kosmidis, Chris
1Denning, David W
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextno_fulltext
addata
aulast
0Kosmidis
1Denning
aufirst
0Chris
1David W
auinit1
0C.
1D.
au
0Kosmidis, Chris
1Denning, David W
atitleRepublished: The clinical spectrum of pulmonary aspergillosis
jtitlePostgraduate Medical Journal
risdate20150701
volume91
issue1077
spage403
issn00325473
abstractThe clinical presentation of Aspergillus lung disease is determined by the interaction between fungus and host. Invasive aspergillosis develops in severely immunocompromised patients, including those with neutropenia, and increasingly in the non-neutropenic host, including lung transplant recipients, the critically ill patients and patients on steroids. A high index of suspicion is required in patients without the classical risk factors as early presentation is usually silent and non-specific, pyrexia uncommon and timely treatment is crucial for survival. Invasive aspergillosis has also been diagnosed in normal hosts after massive exposure to fungal spores. Chronic pulmonary aspergillosis affects patients without obvious immune compromise, but with an underlying lung condition such as COPD or sarcoidosis, prior or concurrent TB or non-tuberculous mycobacterial disease. Aspergillus bronchitis may be responsible for persistent respiratory symptoms in patients with Aspergillus detected repeatedly in sputum without evidence of parenchymal Aspergillus disease, especially in patients with bronchiectasis and cystic fibrosis. Allergic bronchopulmonary aspergillosis affects patients with asthma and cystic fibrosis, and is important to recognise as permanent lung or airways damage may accrue if untreated. Changes in the classification of Aspergillus allergic lung disease have been proposed recently. Cases of extrinsic allergic alveolitis and chronic pulmonary aspergillosis have been observed after Aspergillus exposure. Asymptomatic colonisation of the respiratory tract needs close monitoring as it can lead to clinical disease especially with ongoing immunosuppression. The various syndromes should be viewed as a semicontinuous spectrum of disease and one form may evolve into another depending on the degree of ongoing immunosuppression.
copLondon
pubBMJ Publishing Group LTD
doi10.1136/postgradmedj-2014-206291rep
urlhttp://search.proquest.com/docview/1847948151/
pages403-410
eissn14690756
date2015-07-01
genrearticle
formatjournal
ristypeJOUR